Clinical Trial Update: AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis [Phase 2]

View source ↗

Summary

Phase 2 trial of AZD1775 in advanced acute myeloid leukemia, myelodysplastic syndromes, and myelofibrosis was terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes
• Myelofibrosis

Drugs mentioned

• AZD1775 (Adavosertib)

Snippet

Sponsor: NYU Langone Health | Conditions: Myelofibroses, Acute Myeloid Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2020-06-02